Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Email Promoting Instruments for Compelling Efforts - 2King Charles III says he is reducing cancer treatment schedule in 2026
- 3Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 4Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- 5Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- World’s tallest bridge and biggest museum named ‘greatest places of 2026’
- Exploring the Difficulties of Beginning a Family: Individual Experiences
- Wolf bites woman in a shopping area in Germany's 2nd-biggest city
- Journalists killed by Israeli strike in southern Lebanon
- Nexi expands alliance with PayPal
- Key Business Regulations to Consider While Arranging Your Independent venture
- Israel launches new wave of attacks against Hezbollah in Beirut
- Some Americans say they'll go without health insurance as ACA rates spike
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
